title: Myelodysplastic syndrome successfully treated with adalimumab.
authors.affiliation: Sunnybrook Health Sciences Centre/Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada anca.prica@sunnybrook.ca.
authors.forename: Anca
authors.initials: A
authors.lastname: Prica
authors.affiliation: Sunnybrook Health Sciences Centre/Odette Cancer Centre, University of Toronto, Toronto, Ontario, Canada.
authors.forename: Rena
authors.initials: R
authors.lastname: Buckstein
mesh_terms: D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000627:therapeutic use*; D003424:Crohn Disease / Q000150:complications; D000068256:Darbepoetin alfa; D004334:Drug Administration Schedule; D004921:Erythropoietin / Q000031:analogs & derivatives / Q000627:therapeutic use; D006397:Hematinics / Q000627:therapeutic use; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000175:diagnosis* / Q000188:drug therapy*; D010976:Platelet Count; D016032:Randomized Controlled Trials as Topic; D011961:Receptors, Fc / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D013926:Thrombopoietin / Q000627:therapeutic use; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors* / Q000276:immunology
chemical_list: D000893:Anti-Inflammatory Agents; D061067:Antibodies, Monoclonal, Humanized; D006397:Hematinics; D006454:Hemoglobins; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D014409:Tumor Necrosis Factor-alpha; D004921:Erythropoietin; D000068256:Darbepoetin alfa; D013926:Thrombopoietin; D000068879:Adalimumab; C488777:romiplostim